Biomarkers of drug-induced liver injury
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a major clinical and regulatory challenge. As a result, interest in DILI biomarkers is growing. So far, considerable progress has been made in identification of biomarkers for diagnosis (acetaminophen-cysteine protein adducts), prediction (genetic biomarkers), and prognosis (microRNA-122, high mobility group box 1 protein, keratin-18, glutamate dehydrogenase, mitochondrial DNA). Many of those biomarkers also provide mechanistic insight. The purpose of this chapter is to review major advances in DILI biomarker research over the last decade, and to highlight some of the challenges involved in implementation. Although much work has been done, more liver-specific biomarkers, more DILI-specific biomarkers, and better prognostic biomarkers for survival, are all still needed. Furthermore, more work is needed to define reference intervals and medical decision limits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early indicators of prognosis in fulminant hepatic failure
O'Grady, J. G., Alexander, G. J. M., Hayllar, K. M., & Williams, R. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90081-4 · Cited by 2,085
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“It is commonly encountered during testing of new drugs, and roughly half with early clinical evidence of hepatotoxicity are terminated before reaching the market (Olson et al., 2000).”
BackgroundMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Acetaminophen Overdose: 662 Cases With Evaluation of Oral Acetylcysteine Treatment
Rumack, B. H. (1981) · Archives of Internal Medicine · doi:10.1001/archinte.1981.00340030112020 · Cited by 350
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348 · cited 2×
“Other gene variants associated with DILI affect drug metabolizing enzymes (Huang et al., 2003; Daly et al., 2007; Yimer et al., 2012; Markova et al., 2013; Urban et al., 2014), transporters (Haas et al.”
BackgroundMarques, P. E., Amaral, S. S., Pires, D. A., Nogueira, L. L., Soriani, F. M., Lima, B. H. F., Lopes, G. A. O., Russo, R. C., Ávila, T. V., Melgaço, J. G., et al. (2012) · Hepatology · doi:10.1002/hep.25801 · Cited by 332
High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells
Andersson, U., Yang, H., & Harris, H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.011 · Cited by 309 · cited 2×
“HMGB1 acts as a damageassociated molecular pattern (DAMP) and induces inflammation via receptors on macrophages and other inflammatory cells (Andersson et al., 2018).”
BackgroundAcetaminophen overdose: Incidence, diagnosis and management in 416 patients
Rumack, B. H., & Peterson, R. G. (1978) · Pediatrics · doi:10.1542/peds.62.5s.898 · Cited by 199
James, L. P., Letzig, L., Simpson, P. M., Capparelli, E., Roberts, D. W., Hinson, J. A., Davern, T. J., & Lee, W. M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.026195 · Cited by 175 · cited 1×
“Together, data from studies of protein-derived APAP-CYS in APAP overdose patients have demonstrated that a cutoff of 1 nmol/mL is sensitive and specific for severe hepatotoxicity (ALT ≥1,000 U/L) after APAP overdose (James et al., 2009; Heard et al., 2011; Khandelwal et al., 2011; Alonso et al., 2015).”
BackgroundKrauskopf, J., Caiment, F., Claessen, S. M., Johnson, K. J., Warner, R. L., Schomaker, S. J., Burt, D. A., Aubrecht, J., & Kleinjans, J. C. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu232 · Cited by 93
Cited by
LeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
“DILI cases fall into two major categories: intrinsic/direct hepatotoxicity or idiosyncratic hepatotoxicity, with a third emerging category being indirect mechanisms of hepato-toxicity (that may include gut dysbiosis) [263].”
BackgroundDrug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
“Clinical testing is useful for the detection of DILI but is not indicative of prognosis or etiology (McGill and Jaeschke 2019).”
BackgroundImmune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
“DAMPs, such as high mobility group box-1 (HMGB1), keratin 18 (K18), and adenosine triphosphate (ATP), are currently studied as promising DILI biomarkers and therapeutic targets; this is the case for Acetaminophen (APAP) overdose, a very common cause of DILI in Western countries [23].”
Background
Metadata
- Authors
- McGill, M. R., & Jaeschke, H.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2019
- Volume
- 85
- Pages
- 221-239
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W2922217006
- Cited by
- 78
- References
- 10
- FWCI
- 19.73
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.